Targovax ASA, a clinical stage company focused on developing and commercializing immuno-oncology therapies against solid tumors, has appointed Oystein Soug, currently the Company’s Chief Financial Officer, to the role of Chief Executive Officer (CEO), to replace Gunnar Gårdemyr, the company’s current CEO, who has stepped down.
Gunnar Gårdemyr
The new changes have immediate effect. The company has initiated a search for a new CEO.
Øystein Soug
Jónas Einarsson, Chairman of the Targovax Board of Directors, commented, “On behalf of the Board, I would like to thank Gunnar for his significant contributions to the Company over the past two years. Gunnar has had a key role in building and positioning Targovax and we wish him well for the future.”
Jónas added, “We are delighted to announce the appointment of Oystein as the new CEO of Targovax. He has played a key role as CFO over the past year – successfully guiding us on the path to becoming a publicly-listed company, securing funding for further development of the Company’s ongoing and planned trials. His previous experience as CFO of Algeta, up to its successful product launch and sale to Bayer, gives him a broad range of expertise that will be of significant value to Targovax as we move forward. We are confident in his ability to lead the Company as we approach important milestones in 2017 and 2018 in our innovative clinical pipeline designed to help the patient’s own immune system to fight cancer.”